No Data
No Data
Pace Life Sciences Expands Capacity and Capability With Acquisition of Catalent's Analytical Services Laboratory in Research Triangle Park
Catalent Stock: Is CTLT Outperforming the Healthcare Sector?
Catalent Cut to Neutral at Baird as Analyst Unable to Find Valuation in a Deal Break
Catalent Analyst Ratings
Baird Downgrades Catalent to Neutral From Outperform, Price Target Is $63.50
Baird Downgrades Catalent(CTLT.US) to Hold Rating, Maintains Target Price $63.5
Baird analyst Eric Coldwell downgrades $Catalent(CTLT.US)$ to a hold rating, and maintains the target price at $63.5.According to TipRanks data, the analyst has a success rate of 53.9% and a total